ResMed
- Revenue$3.2 BFY, 2021
- Market Capitalization$30.8 B2022-06-24
OverviewSuggest Edit
ResMed is a company that specializes in digital health and cloud-connected medical devices. It operates in two segments, the Sleep and Respiratory Care segment and the Software as a Service (SaaS). The company develops, manufactures, and distributes medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. ResMed offers a number of products, including airflow generators, diagnostic products, mask systems, cloud-connected CPAP machines, cloud-connected ventilators, portable oxygen, headgear, and other accessories. Furthermore, the company provides a network of out-of-hospital healthcare management solutions designed to help providers deliver personalized care.
| Type | Public | |
| Founded | 1989 | |
| HQ | San Diego, CA, US | Map |
| Website | resmed.com | |
| Employee Ratings | ||
| Overall Culture | A+ | More |
Recent NewsAll News
- ResMed buys German digital healthcare platform MEDIFOX DAN for $1 billion
- ResMed to Acquire MEDIFOX DAN, a German Leader in Out-of-Hospital Software Solutions
- ResMed Announces Participation in the 43rd Annual Goldman Sachs Global Healthcare Conference
- ResMed Announces Participation in the 42nd Annual William Blair Growth Stock Conference
Key People/Management at ResMed
Michael Mick Farrell
CEO
Rob Douglas
President and Chief Operating Officer
David Pendarvis
Chief Administrative Officer, Global General Counsel
Jim Hollingshead
President, Sleep Business
McHale Richie
Chief Transformation Officer
Raj Sodhi
President, SaaS Business
ResMed Office Locations
ResMed has offices in San Diego, Bella Vista, Kontich, São Paulo and in 18 other locations
San Diego, CA, US (HQ)
9001 Spectrum Center Blvd
Bella Vista, AU
1 Elizabeth Macarthur Dr
Kontich, BE
50 Grote Steenweg
São Paulo, BR
Roque Petroni Junior Avenue, 850 Bacaetava Tower
Chaoyang, CN
12th Floor, Building, 12 Taiyanggong Middle Rd, Chaoyang Qu
Espoo, FI
3 Hevosenkenkä
ResMed Financials and Metrics
ResMed Revenue
ResMed's revenue was reported to be $3.2 b in FY, 2021 which is a 8.1% increase from the previous period.
| USD | |
|---|---|
Revenue (Q1, 2022) | 904.0m |
Gross profit (Q1, 2022) | 506.3m |
Gross profit margin (Q1, 2022), % | 56% |
Net income (Q1, 2022) | 203.6m |
EBIT (Q1, 2022) | 261.9m |
Market capitalization (24-Jun-2022) | 30.8b |
Closing stock price (24-Jun-2022) | 211.5 |
Cash (30-Sept-2021) | 276.1m |
EV | 31.5b |
ResMed's current market capitalization is $30.8 b.
Annual
Annual
Annual
Quarterly
| USD | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 |
|---|---|---|---|---|---|---|---|
Net Income | 120.1m | 280.7m | 443.8m | 178.4m | 357.9m | 279.4m | 203.6m |
Depreciation and Amortization | 38.0m | 77.1m | 116.3m | 39.5m | 80.0m | 120.0m | 39.1m |
Inventories | (14.2m) | (28.3m) | (22.6m) | (52.4m) | (34.2m) | (48.4m) | (56.0m) |
Accounts Payable | (30.1m) | (88.9m) | (57.3m) | (61.3m) | (99.3m) | 158.1m | (293.3m) |
| USD | FY, 2019 |
|---|---|
EV/EBIT | 32.1 x |
EV/CFO | 40.6 x |
Revenue/Employee | 360.0k |
Debt/Equity | 0.6 x |
Debt/Assets | 0.3 x |
Financial Leverage | 2 x |
P/E Ratio | 43.6 |
ResMed Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Propeller Health | December 07, 2018 | |
| Matrixcare | November 05, 2018 | $750 m |
ResMed Revenue Breakdown
ResMed revenue breakdown by business segment: 11.7% from Software as a Service, 37.9% from Masks and Other and 50.4% from Devices
ResMed revenue breakdown by geographic segment: 38.6% from Rest of the World and 61.4% from United States
ResMed Cybersecurity Score
ResMed Environment, Social & Governance (ESG) Ratings
ResMed Online and Social Media Presence
ResMed's Trends
ResMed Company Culture
Overall Culture
A+
81/100
CEO Rating
A+
90/100
Compensation
A
81/100
Diversity
B
74/100
ResMed News and Updates
June 14, 2022
ResMed buys German digital healthcare platform MEDIFOX DAN for $1 billion
Software and services investor Hg has sold German digital care platform MEDIFOX DAN to San Diego-based ResMed in a transaction valuing the business at an enterprise value of around $1 billion. The new...
June 14, 2022
ResMed to Acquire MEDIFOX DAN, a German Leader in Out-of-Hospital Software Solutions
SAN DIEGO and HILDESHEIM, Germany, June 14, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced a definitive agreement to acquire privately held MEDIFOX DAN, a German leader in out-of-hospital software solutions for providers in major settings across the care continuum, from Hg, …
June 07, 2022
ResMed Announces Participation in the 43rd Annual Goldman Sachs Global Healthcare Conference
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Tuesday, June 14, 2022, beginning at approximately 1:20 p.m. (Pacific Daylight T…
June 01, 2022
ResMed Announces Participation in the 42nd Annual William Blair Growth Stock Conference
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will present at the William Blair Growth Stock Conference on Wednesday, June 8, 2022, beginning at approximately 9:20 a.m. (Central Daylight Time) at the Lo…
May 25, 2022
ResMed Announces Participation in the 38th Annual Bernstein Strategic Decisions Conference
SAN DIEGO, May 25, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a fireside chat at the Bernstein Strategic Decisions Conference on Wednesday, June 1, 2022, beginning at approximately 1:30 p.m. (Eastern Daylight Tim…
May 18, 2022
Even 2 Hours of PAP Therapy per Night Benefits Sleep Apnea Sufferers: ResMed Study
SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Sleep apnea sufferers can gain health benefits from PAP (positive airway pressure) treatment in as little as two hours per night, according to a study led by ResMed (NYSE: RMD, ASX: RMD) and presented at the American Thoracic Society’s annual Interna…
ResMed Blogs
October 07, 2019
Cerner and ResMed Join Forces to Connect Health Networks and the Home
Two industry leaders collaborate to improve out-of-hospital care transitions and chronic disease management
September 24, 2019
ResMed Named 2019 Dealmaker of the Year by Medtech Insight
5 key acquisitions drove global connected health leader’s award win
ResMed Frequently Asked Questions
When was ResMed founded?
ResMed was founded in 1989.
Who are ResMed key executives?
ResMed's key executives are Michael Mick Farrell, Rob Douglas and David Pendarvis.
How many employees does ResMed have?
ResMed has 7,970 employees.
What is ResMed revenue?
Latest ResMed annual revenue is $3.2 b.
What is ResMed revenue per employee?
Latest ResMed revenue per employee is $401.1 k.
Who are ResMed competitors?
Competitors of ResMed include Hillrom, DeVilbiss and Apex Medical.
Where is ResMed headquarters?
ResMed headquarters is located at 9001 Spectrum Center Blvd, San Diego.
Where are ResMed offices?
ResMed has offices in San Diego, Bella Vista, Kontich, São Paulo and in 18 other locations.
How many offices does ResMed have?
ResMed has 22 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies